MS Imaging Applications in Pharma & Chemical Biology
February 22 | Mannheim, Germany
9:30 – 10:00 Rima Ait-Belkacem, ImaBiotech, Lille, France: Quantitative MSI in metabolite & biomarker studies
About Dr. Ait-Belkacem, R&D Manager
After having obtained her Master degree in Oncology Science and Oncopharmacology, a PhD in Oncology and Imaging Mass Spectrometry applied to Glioblastoma cancer; and a Post-Doc in Cancer Biology and Proteomics, Dr. Ait-Belkacem, R&D Manager, has the ambition to develop the oncology research field at ImaBiotech. Currently, her team is mainly leading the way in Immuno-Oncology (I-O) research.
ImaBiotech supports pharmaceutical industry with innovative Imaging services that predict more accurately which treatment will work in stratified population.
ImaBiotech is a Contract Research Organization (CRO) with two facilities one in Boston (MA) and one in France. The company offers innovative services to the pharmaceutical research to provide better drug efficacy and toxicity evaluations from preclinical to clinical stages, making better and safer drugs.
Services are based on different imaging techniques combined to Quantitative Mass Spectrometry a technology developed and constantly improved by ImaBiotech. Quantitative Mass Spectrometry (QMSI) has been developed for decades and allows to detect elements and molecules without labelling. ImaBiotech has developed the quantitative aspects through many patents making ImaBiotech the worldwide leader in this field. QMSI is a game changer of the pharmaceutical industry in all therapeutic areas. While actual techniques provide global information, this molecular technique brings deeper information about drug localization and its pharmacology effects to recover disease tissues and damaged cells. This increases the interpretation of drug efficacy and toxicity improving drugs and improving time to market. To interpret datas we’ve developed, thanks to our patents, two softwares called Quantinetix and Multimaging to interpret pharmacology in tissue.